Hester Biosciences Ltd
Hester Biosciences Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #80 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Next half of FY26 expected to show stronger performance, covering up for the subdued Q2 results. The company anticipates stronger performance in the second half of FY26, aiming to cover up for a relatively damp Q2.
From Hester Biosciences Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Next half of FY26 expected to show stronger performance, covering up for the subdued Q2 results.
- Strategic focus on reducing dependency on tender-based revenues, aiming for a more balanced portfolio.
- Poultry healthcare division showing volume-led growth: 18% in Q2 and 10% in H1 FY26.
- New vaccine launches, such as H9N2 and avian influenza vaccine (post-manufacturing license expected by December), to enhance export and domestic sales.
- Pet Care segment expected to grow steadily, leveraging existing capacities without major capex.
- Anticipated launch of Lumpy Skin Disease (LSD) vaccine in India by mid-next financial year.
2 more points from Hester Biosciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Hester Biosciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No major new capex planned for the next 2-3 years in the current segment; existing capacities provide a huge runway based on demand (Rajiv Gandhi, Page 12).
- Some smaller capex will occur as part of progress and renovations in existing plants, but no large-scale investments anticipated (Rajiv Gandhi, Page 12).
- Capital work in progress of INR182 crore at India plant expected to be fully capitalized by March, which will significantly enhance production capacity (Priya Gandhi, Page 3).
- Routine capital expenditure planned for the coming years apart from the existing expansion (Priya Gandhi, Page 9).
2 more points from Hester Biosciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hester Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The current quarter witnessed delays in government-led immunization programs for PPR and Lumpy Skin Disease, impacting order execution and causing a 50% degrowth in Animal Healthcare division in Q2.
- These delays are timing-related and not due to lack of demand; a pickup in orders is anticipated particularly in Q4 as execution timelines normalize.
- Nepal operations were affected by timing of institutional orders and temporary disturbances but expect institutional execution to resume in H2.
- There is readiness at Hester Biosciences to meet rollout demands once government programs restart.
Hester Biosciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹100 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hester Bios's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Hester Biosciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Hester Biosciences Ltd Q2 FY26 results?
Next half of FY26 expected to show stronger performance, covering up for the subdued Q2 results. The company anticipates stronger performance in the second half of FY26, aiming to cover up for a relatively damp Q2.
What is Hester Biosciences Ltd share price analysis?
Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.7 with a market cap of ₹2,054 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hester Biosciences Ltd planning capital expenditure?
No major new capex planned for the next 2-3 years in the current segment; existing capacities provide a huge runway based on demand (Rajiv Gandhi, Page 12).
Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.